Is Ensysce Biosciences going out of business?

ENSYSCE BIOSCIENCES, INC. (ENSC) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ENSYSCE BIOSCIENCES, INC. (ENSC) scores 1 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 451.99% (YoY)

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $677K of cash and short-term investments against $16.9M of annual burn. Adjusted shares outstanding increased 452.0% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

5.2% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 451.99% (YoY)
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• FCF margin: -375.36%
• Interest coverage: -1507.3x
• Cash Runway (years): 0.04y
• Revenue CAGR (3Y): 26.16%
• Revenue growth YoY: -15.10% (YoY)
• Return on Assets: -426.89%
• Debt Maturity Runway: 0% long-term (Near-term refinancing risk)
• Cash Burn Deceleration: -28.80% QoQ improvement (Worsening)
• Price / Sales: 2.0x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.